Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease

References

• Arnold AC, Okamoto LE, Gamboa A, et al. Mineralocorticoid receptor activation contributes to the supine hypertension of autonomic failure. Hypertension. 2016;67:424–429.
   PubMed Web of Science ®Google Scholar
• Bach JP, Ziegler U, Deuschl G, et al. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord. 2011;26:2286–2290.
   PubMed Web of Science ®Google Scholar
• Kalia LV, Lang AE. Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD. Nat Rev Neurol. 2016;12:65–66.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464–474.
   PubMed Web of Science ®Google Scholar
• Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49–60.
   PubMed Web of Science ®Google Scholar
• Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord. 2008;23 Suppl 3:S497–508.
   PubMed Web of Science ®Google Scholar
• Olanow CW. The pathogenesis of cell death in Parkinson’s disease–2007. Mov Disord. 2007;22 Suppl 17:S335–342.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–840.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Sampaio C, Rascol O. Disease-modifying strategies in Parkinson’s Disease. In: Jankovik J, Tolosa E, editors. Parkinson’s disease and movement disorders. Philadelphia (PA): Wolters Kluwer; 2015.
   Google Scholar
• Ferrario CM. The renin-angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol. 1990;15 Suppl 3:S1–5.
   PubMed Web of Science ®Google Scholar
• Mascolo A, Sessa M, Scavone C, et al. New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): focus on cardiovascular and neurological diseases. Int J Cardiol. 2017;227:734–742.
   PubMed Web of Science ®Google Scholar
• Ciobica A, Bild W, Hritcu L, et al. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009;109:171–180.
   PubMed Web of Science ®Google Scholar
• De Bundel D, Smolders I, Vanderheyden P, et al. Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy. CNS Neurosci Ther. 2008;14:315–339.
   PubMed Web of Science ®Google Scholar
• Mertens B, Vanderheyden P, Michotte Y, et al. The role of the central renin-angiotensin system in Parkinson’s disease. J Renin Angiotensin Aldosterone Syst. 2010;11:49–56.
   PubMed Web of Science ®Google Scholar
• Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol. 2015;11:242–252.
   PubMed Web of Science ®Google Scholar
• Arroja MM, Reid E, McCabe C. Therapeutic potential of the renin angiotensin system in ischaemic stroke. Exp Transl Stroke Med. 2016;8:8.
   PubMedGoogle Scholar
• Inagami T, Kambayashi Y, Ichiki T, et al. Angiotensin receptors: molecular biology and signalling. Clin Exp Pharmacol Physiol. 1999;26:544–549.
   PubMed Web of Science ®Google Scholar
• Karamyan VT, Arsenault J, Escher E, et al. Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain. Endocrine. 2010;37:442–448.
   PubMed Web of Science ®Google Scholar
• Ge J, Barnes NM. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol. 1996;297:299–306.
   PubMed Web of Science ®Google Scholar
• Garrido-Gil P, Rodriguez-Perez AI, Fernandez-Rodriguez P, et al. Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells. Brain Struct Funct. 2017;222:2559–2571.
   PubMed Web of Science ®Google Scholar
• Kalra J, Prakash A, Kumar P, et al. Cerebroprotective effects of RAS inhibitors: beyond their cardio-renal actions. J Renin Angiotensin Aldosterone Syst. 2015;16:459–468.
   PubMed Web of Science ®Google Scholar
• Valenzuela R, Costa-Besada MA, Iglesias-Gonzalez J, et al. Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration. Cell Death Dis. 2016;7:e2427.
   PubMed Web of Science ®Google Scholar
• Martinez-Pinilla E, Rodriguez-Perez AI, Navarro G, et al. Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum. Biochem Pharmacol. 2015;96:131–142.
   PubMed Web of Science ®Google Scholar
• Simonnet G, Giorguieff-Chesselet MF. Stimulating effect of angiotensin II on the spontaneous release of newly synthetized [3H]dopamine in rat striatal slices. Neurosci Lett. 1979;15:153–158.
   PubMed Web of Science ®Google Scholar
• Mendelsohn FA, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 1993;613:221–229.
   PubMed Web of Science ®Google Scholar
• Brown DC, Steward LJ, Ge J, et al. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol. 1996;118:414–420.
   PubMed Web of Science ®Google Scholar
• Mertens B, Vanderheyden P, Michotte Y, et al. Direct angiotensin II type 2 receptor stimulation decreases dopamine synthesis in the rat striatum. Neuropharmacology. 2010;58:1038–1044.
   PubMed Web of Science ®Google Scholar
• Dwoskin LP, Jewell AL, Cassis LA. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum. Naunyn Schmiedebergs Arch Pharmacol. 1992;345:153–159.
   PubMed Web of Science ®Google Scholar
• Dominguez-Meijide A, Villar-Cheda B, Garrido-Gil P, et al. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson’s disease treated with L-DOPA. Neuropharmacology. 2014;76 Pt A:156–168.
   PubMed Web of Science ®Google Scholar
• Jenkins TA, Mendelsohn FA, Chai SY. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J Neurochem. 1997;68:1304–1311.
   PubMed Web of Science ®Google Scholar
• Stragier B, Sarre S, Vanderheyden P, et al. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J Neurochem. 2004;90:1251–1257.
   PubMed Web of Science ®Google Scholar
• Villar-Cheda B, Rodriguez-Pallares J, Valenzuela R, et al. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson’s disease. Eur J Neurosci. 2010;32:1695–1706.
   PubMed Web of Science ®Google Scholar
• Villar-Cheda B, Dominguez-Meijide A, Valenzuela R, et al. Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol Aging. 2014;35:1726–1738.
   PubMed Web of Science ®Google Scholar
• Grammatopoulos TN, Ahmadi F, Jones SM, et al. Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death. Brain Res. 2005;1045:64–71.
   PubMed Web of Science ®Google Scholar
• Grammatopoulos TN, Jones SM, Ahmadi FA, et al. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener. 2007;2:1.
   PubMed Web of Science ®Google Scholar
• Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, et al. The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem. 2009;109:656–669.
   PubMed Web of Science ®Google Scholar
• Munoz A, Garrido-Gil P, Dominguez-Meijide A, et al. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson’s disease. Involvement of vascular endothelial growth factor and interleukin-1beta. Exp Neurol. 2014;261:720–732.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pallares J, Quiroz CR, Parga JA, et al. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci. 2004;20:1489–1498.
   PubMed Web of Science ®Google Scholar
• Villar-Cheda B, Dominguez-Meijide A, Joglar B, et al. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis. 2012;47:268–279.
   PubMed Web of Science ®Google Scholar
• Lu J, Wu L, Jiang T, et al. Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson’s disease in CATH.a cells. Neurotoxicol Teratol. 2015;47:16–24.
   PubMed Web of Science ®Google Scholar
• Ou Z, Jiang T, Gao Q, et al. Mitochondrial-dependent mechanisms are involved in angiotensin II-induced apoptosis in dopaminergic neurons. J Renin Angiotensin Aldosterone Syst. 2016;17.
   PubMed Web of Science ®Google Scholar
• Gao Q, Jiang T, Zhao HR, et al. Activation of autophagy contributes to the Angiotensin II-triggered apoptosis in a dopaminergic neuronal cell line. Mol Neurobiol. 2016;53:2911–2919.
   PubMed Web of Science ®Google Scholar
• Grammatopoulos TN, Outeiro TF, Hyman BT, et al. Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Biochem Biophys Res Commun. 2007;363:846–851.
   PubMed Web of Science ®Google Scholar
• Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, et al. Microglial TNF-alpha mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014;62:145–157.
   PubMed Web of Science ®Google Scholar
• Hiroki J, Shimokawa H, Higashi M, et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol. 2004;37:537–546.
   PubMed Web of Science ®Google Scholar
• Valenzuela R, Barroso-Chinea P, Villar-Cheda B, et al. Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. J Neuropathol Exp Neurol. 2010;69:1130–1142.
   PubMed Web of Science ®Google Scholar
• Chiueh CC, Markey SP, Burns RS, et al. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull. 1984;20:548–553.
   PubMed Web of Science ®Google Scholar
• Blesa J, Phani S, Jackson-Lewis V, et al. Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol. 2012;2012:1–10.
   PubMedGoogle Scholar
• Lopez-Real A, Rey P, Soto-Otero R, et al. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J Neurosci Res. 2005;81:865–873.
   PubMed Web of Science ®Google Scholar
• Sonsalla PK, Coleman C, Wong LY, et al. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. Exp Neurol. 2013;250:376–383.
   PubMed Web of Science ®Google Scholar
• Kurosaki R, Muramatsu Y, Kato H, et al. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Eur Neuropsychopharmacol. 2005;15:57–67.
   PubMed Web of Science ®Google Scholar
• Kurosaki R, Muramatsu Y, Imai Y, et al. Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice. Neurol Res. 2004;26:644–657.
   PubMed Web of Science ®Google Scholar
• Jenkins TA, Wong JY, Howells DW, et al. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J Neurochem. 1999;73:214–219.
   PubMed Web of Science ®Google Scholar
• Mertens B, Varcin M, Michotte Y, et al. The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death. Eur J Neurosci. 2011;34:1141–1148.
   PubMed Web of Science ®Google Scholar
• Wu L, Tian YY, Shi JP, et al. Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of candesartan cilexitil in the rotenone rat model of Parkinson’s disease. Neurosci Lett. 2013;548:50–55.
   PubMed Web of Science ®Google Scholar
• Sathiya S, Ranju V, Kalaivani P, et al. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of alpha-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. Neuropharmacology. 2013;73:98–110.
   PubMed Web of Science ®Google Scholar
• Garrido-Gil P, Joglar B, Rodriguez-Perez AI, et al. Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson’s disease. J Neuroinflammation. 2012;9:38.
   PubMed Web of Science ®Google Scholar
• Tong Q, Wu L, Jiang T, et al. Inhibition of endoplasmic reticulum stress-activated IRE1alpha-TRAF2-caspase-12 apoptotic pathway is involved in the neuroprotective effects of telmisartan in the rotenone rat model of Parkinson’s disease. Eur J Pharmacol. 2016;776:106–115.
   PubMed Web of Science ®Google Scholar
• Munoz A, Rey P, Guerra MJ, et al. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology. 2006;51:112–120.
   PubMed Web of Science ®Google Scholar
• Galehdar Z, Swan P, Fuerth B, et al. Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. J Neurosci. 2010;30:16938–16948.
   PubMed Web of Science ®Google Scholar
• Schintu N, Frau L, Ibba M, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur J Neurosci. 2009;29:954–963.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord. 2007;22:1379–1389; quiz 523.
   Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S2–41.
   PubMed Web of Science ®Google Scholar
• Lang AE, Melamed E, Poewe W, et al. Trial designs used to study neuroprotective therapy in Parkinson’s disease. Mov Disord. 2013;28:86–95.
   PubMed Web of Science ®Google Scholar
• Zawada WM, Mrak RE, Biedermann J, et al. Loss of angiotensin II receptor expression in dopamine neurons in Parkinson’s disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun. 2015;3:9.
   PubMed Web of Science ®Google Scholar
• Rocha NP, Scalzo PL, Barbosa IG, et al. Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson’s disease. J Neurol Sci. 2016;368:235–239.
   PubMed Web of Science ®Google Scholar
• Konings CH, Kuiper MA, Bergmans PL, et al. Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson’s disease. Clin Chim Acta. 1994;231:101–106.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Yueh KC, Chang DC, et al. Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson’s disease. J Neurol Sci. 2002;199:25–29.
   PubMed Web of Science ®Google Scholar
• Mellick GD, Buchanan DD, McCann SJ, et al. The ACE deletion polymorphism is not associated with Parkinson’s disease. Eur Neurol. 1999;41:103–106.
   PubMed Web of Science ®Google Scholar
• Reardon KA, Mendelsohn FA, Chai SY, et al. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson’s disease. Aust N Z J Med. 2000;30:48–53.
   PubMedGoogle Scholar
• Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008;70:1438–1444.
   PubMed Web of Science ®Google Scholar
• Ritz B, Rhodes SL, Qian L, et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67:600–606.
   PubMed Web of Science ®Google Scholar
• Lee YC, Lin CH, Wu RM, et al. Antihypertensive agents and risk of Parkinson’s disease: a nationwide cohort study. PLoS One. 2014;9:e98961.
   PubMed Web of Science ®Google Scholar
• Ancelin ML, Carriere I, Scali J, et al. Angiotensin-converting enzyme gene variants are associated with both cortisol secretion and late-life depression. Transl Psychiatry. 2013;3:e322.
   PubMed Web of Science ®Google Scholar
• Su G, Dou H, Zhao L, et al. The angiotensin-converting enzyme (ACE) I/D polymorphism in Parkinson’s disease. J Renin Angiotensin Aldosterone Syst. 2015;16:428–433.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2009;72:578–579.
   PubMed Web of Science ®Google Scholar
• Grace AA. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord. 2008;23 Suppl 3:S560–569.
   PubMed Web of Science ®Google Scholar
• Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med. 2009;169:1195–1202.
   PubMed Web of Science ®Google Scholar
• Aulakh GK, Sodhi RK, Singh M. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci. 2007;81:615–639.
   PubMed Web of Science ®Google Scholar
• Culman J, Jacob T, Schuster SO, et al. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important? Naunyn Schmiedebergs Arch Pharmacol. 2017;390:949–959.
   Web of Science ®Google Scholar
• Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens. 2015;28:289–299.
   PubMed Web of Science ®Google Scholar
• Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, et al. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson’s disease. Mov Disord. 2013;28:1337–1342.
   PubMed Web of Science ®Google Scholar
• Labandeira-Garcia JL, Garrido-Gil P, Rodriguez-Pallares J, et al. Brain renin-angiotensin system and dopaminergic cell vulnerability. Front Neuroanat. 2014;8:67.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:501–505.
   PubMed Web of Science ®Google Scholar
• Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015;125:26–46.
   PubMed Web of Science ®Google Scholar